Glypican-3: A molecular marker for the detection and treatment of hepatocellular carcinoma(☆)

Hepatocellular carcinoma (HCC) is a malignant tumor with a fairly poor prognosis (5-year survival of less than 50%). Using sorafenib, the only food and drug administration (FDA)-approved drug, HCC cannot be effectively treated; it can only be controlled at most for a couple of months. There is a gre...

Descripción completa

Detalles Bibliográficos
Autores principales: Shih, Tsung-Chieh, Wang, Lijun, Wang, Hsiao-Chi, Wan, Yu-Jui Yvonne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7771890/
https://www.ncbi.nlm.nih.gov/pubmed/33384879
http://dx.doi.org/10.1016/j.livres.2020.11.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7771890/
https://www.ncbi.nlm.nih.gov/pubmed/33384879
http://dx.doi.org/10.1016/j.livres.2020.11.003

Ejemplares similares